Literature DB >> 17316369

Francisella tularensis vaccines.

Kate F Griffin1, Petra C F Oyston, Richard W Titball.   

Abstract

Francisella tularensis is the causative agent of tularaemia, a disease which occurs naturally in some countries in the northern hemisphere. Recently, there has been a high level of interest in devising vaccines against the bacterium because of the potential for it to be used as a bioterrorism agent. Previous human volunteer studies have shown that a strain of F. tularensis [the live vaccine strain (LVS)] that has been attenuated by laboratory passage is effective in humans as a vaccine against airborne disease. However, for a variety of reasons it seems unlikely that the LVS strain will be licensed for use in humans. Against this background there is an effort to devise a licensable vaccine against tularaemia. The prospects for a killed whole-cell subunit of live attenuated vaccine are reviewed. A rationally attenuated mutant seems the most likely route to a new tularaemia vaccine.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17316369     DOI: 10.1111/j.1574-695X.2007.00219.x

Source DB:  PubMed          Journal:  FEMS Immunol Med Microbiol        ISSN: 0928-8244


  25 in total

1.  A Francisella tularensis live vaccine strain (LVS) mutant with a deletion in capB, encoding a putative capsular biosynthesis protein, is significantly more attenuated than LVS yet induces potent protective immunity in mice against F. tularensis challenge.

Authors:  Qingmei Jia; Bai-Yu Lee; Richard Bowen; Barbara Jane Dillon; Susan M Som; Marcus A Horwitz
Journal:  Infect Immun       Date:  2010-07-19       Impact factor: 3.441

2.  Impact of Francisella tularensis pilin homologs on pilus formation and virulence.

Authors:  Nicole M Ark; Barbara J Mann
Journal:  Microb Pathog       Date:  2011-05-13       Impact factor: 3.738

3.  Generation and characterization of hybridoma antibodies for immunotherapy of tularemia.

Authors:  Zhaohua Lu; Marly I Roche; Julia H Hui; Berkay Unal; Philip L Felgner; Sunita Gulati; Guillermo Madico; Jacqueline Sharon
Journal:  Immunol Lett       Date:  2007-08-08       Impact factor: 3.685

4.  Identification of a dominant CD4 T cell epitope in the membrane lipoprotein Tul4 from Francisella tularensis LVS.

Authors:  Michael D Valentino; Lucinda L Hensley; Denise Skrombolas; Pamela L McPherson; Matthew D Woolard; Thomas H Kawula; Jeffrey A Frelinger; John G Frelinger
Journal:  Mol Immunol       Date:  2009-02-23       Impact factor: 4.407

Review 5.  An approach to the identification of T cell epitopes in the genomic era: application to Francisella tularensis.

Authors:  Michael Valentino; John Frelinger
Journal:  Immunol Res       Date:  2009-02-11       Impact factor: 2.829

6.  Characterization of a Unique Outer Membrane Protein Required for Oxidative Stress Resistance and Virulence of Francisella tularensis.

Authors:  Maha Alqahtani; Zhuo Ma; Harshada Ketkar; Ragavan Varadharajan Suresh; Meenakshi Malik; Chandra Shekhar Bakshi
Journal:  J Bacteriol       Date:  2018-03-26       Impact factor: 3.490

Review 7.  Working toward the future: insights into Francisella tularensis pathogenesis and vaccine development.

Authors:  Roger D Pechous; Travis R McCarthy; Thomas C Zahrt
Journal:  Microbiol Mol Biol Rev       Date:  2009-12       Impact factor: 11.056

Review 8.  Vaccines against tularemia.

Authors:  Eileen M Barry; Leah E Cole; Araceli E Santiago
Journal:  Hum Vaccin       Date:  2009-12-11

9.  Mast cells inhibit intramacrophage Francisella tularensis replication via contact and secreted products including IL-4.

Authors:  Jyothi M Ketavarapu; Annette R Rodriguez; Jieh-Juen Yu; Yu Cong; Ashlesh K Murthy; Thomas G Forsthuber; M Neal Guentzel; Karl E Klose; Michael T Berton; Bernard P Arulanandam
Journal:  Proc Natl Acad Sci U S A       Date:  2008-06-30       Impact factor: 11.205

10.  TLR-dependent control of Francisella tularensis infection and host inflammatory responses.

Authors:  Allison L Abplanalp; Ian R Morris; Bijaya K Parida; Judy M Teale; Michael T Berton
Journal:  PLoS One       Date:  2009-11-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.